Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO

NCT05583526 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05583526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05583526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
December 1, 2022
Completion date
February 5, 2026
Enrollment
607 (actual)
Sites
115

Conditions

As the registry lists them; a condition with its own page is linked.

active nonsegmental vitiligo, stable nonsegmental vitiligo